drugset

drugset / Trial / NCT05023551

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

NCT05023551 ↗

Phase 0 Active not recruiting 39 enrolled Sumitomo Pharma America, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a study of DSP-0390 in patients with recurrent high grade glioma.

Timeline

Start: 2021-09-08
Primary completion: 2026-09-30
Completion: 2026-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DSP-0390	Small molecule	—	Oral

Indications